Phase 2 N=50 Study Of Ispinesib In Subjects With Breast Cancer
Neoplasms, Breast
Primary: Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib — 8 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=178 Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
Kidney Transplantation
Primary: Kaplan-Meier Analysis of Percentage of Participants With Clinically Significant Infection by Visit — 4.69; 8.33; 3.70; 7.81 Percentage of Participants — p=0.6694
Phase 2 N=37 Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver
Fatty Liver
Primary: Number of Participants With Improvement of >= 2 Points in NAFLD Activity Score (NAS) — 8; 9 Participants
Phase 2 N=12 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1
Neimann-Pick Disease
Primary: Number of Participants With Tolerabilty of 200 mg Vorinostat in Niemann-Pick Disease, Type C1 — 12 Participants
Phase 2 N=85 Study of AR-13324 in Patients With Elevated Intraocular Pressure
Ocular Hypertension · Open Angle Glaucoma
Primary: Intraocular Pressure (IOP) — 25.80; 26.02; 26.50; 25.17 mmHg
Phase 2 N=65 Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
Thrombocytopenia
Primary: Number of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study — 1; 6; 12; 9 Participants…
Phase 2 N=68 A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) — 4; 5; 7; 6 Participants
Phase 2 N=24 A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics
Asthma
Primary: Late Asthmatic Response (LAR): Minimum FEV1 Between 4-10 Hours After Allergen Challenge on Day 13 of Each Treatment Period — -0.903; -0.663; -0.638; -0.446 Liters
Phase 2 N=44 Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders
Alcohol Reactivity
Primary: Cognitive Function as Measured by Omissions on the CPT — 1.78; 1.28; 4.76; 0.98 Number of Omissions
Phase 2 N=323 Integrated Biomarker And Imaging Study - 2
Atherosclerosis
Primary: Mean Circulating High Sensitivity C- Reactive Protein (Hs-CRP) Levels at Week 52. — 1.034; 0.913 mg per litre (mg/L) — p=0.348
Phase 2 N=53 Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea
Sleep Apnea, Obstructive · Diabetes Mellitus
Primary: Absolute Change in Brachial Artery Flow-mediated Dilation (FMD). — 2.26; 1.59 percentage of brachial artery diameter
Phase 2 N=540 Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children
Malaria
Primary: Number of Subjects With Serious Adverse Events (SAEs) — 10; 19; 5; 13 Participants
Phase 2 N=15 A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy
Healthy Volunteers With Ileostomy
Primary: Ceftriaxone Concentration in Intestinal Chyme Period 1 — 0.00; 0.00; 5.60; 150.90 ug/mL
Phase 2 N=40 Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric Cancer · Esophageal Neoplasms
Primary: Objective Response (Complete, Partial, Stable and Progression) — 0; 7; 22; 9 participants
Phase 2 N=20 Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
Acromegaly
Primary: Participants With Trough Human Growth Hormone < 2.5 ug/mL — 1; 8; 4; 6 participants with trough hGH < 2.5 µg/mL